Panelists discuss how aflibercept 8 mg maintains a safety profile similar to 2 mg and how workflow, systemic risk, and ...
Panelists discuss how clinicians manage suboptimal responders by focusing on stability rather than complete dryness, using ...
A large international study 1 published in the British Journal of Ophthalmology has extended the knowledge about monkeypox ...
The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...
Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians ...
Faster thinning of cpRNFL and mGCIPL is associated with visual field progression in glaucoma, with rates of –1.02 and –1.04 ...
The FDA issued a CRL for ONS-5010, citing the need for additional confirmatory efficacy evidence despite previous trials ...
Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, ...
Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins much ...
The PRIMA system is a subretinal implant designed to restore central vision in GA patients by replacing failed photoreceptors ...
FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...
Refractory dry eye in patients with systemic comorbidities can be challenging to manage because the underlying condition or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback